Equities research analysts forecast that STRATA Skin Sciences Inc (NASDAQ:SSKN) will post $7.64 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for STRATA Skin Sciences’ earnings. The lowest sales estimate is $7.60 million and the highest is $7.67 million. STRATA Skin Sciences reported sales of $7.48 million during the same quarter last year, which indicates a positive year over year growth rate of 2.1%. The business is expected to report its next earnings report on Thursday, November 8th.
According to Zacks, analysts expect that STRATA Skin Sciences will report full year sales of $29.70 million for the current financial year, with estimates ranging from $29.40 million to $30.00 million. For the next year, analysts anticipate that the firm will report sales of $34.15 million, with estimates ranging from $33.80 million to $34.50 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover STRATA Skin Sciences.
STRATA Skin Sciences (NASDAQ:SSKN) last issued its earnings results on Monday, August 13th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.01. The company had revenue of $7.53 million for the quarter, compared to analysts’ expectations of $6.84 million. STRATA Skin Sciences had a negative net margin of 63.07% and a negative return on equity of 27.01%.
Shares of SSKN stock opened at $3.50 on Thursday. The company has a current ratio of 4.77, a quick ratio of 4.20 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $109.89 million, a PE ratio of 1.76 and a beta of 0.69. STRATA Skin Sciences has a 52-week low of $1.06 and a 52-week high of $3.88.
Institutional investors have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC bought a new position in STRATA Skin Sciences in the 2nd quarter valued at about $4,261,000. Menora Mivtachim Holdings LTD. bought a new position in STRATA Skin Sciences in the 2nd quarter valued at about $1,138,000. Renaissance Technologies LLC raised its holdings in STRATA Skin Sciences by 164.6% in the 2nd quarter. Renaissance Technologies LLC now owns 293,499 shares of the medical device company’s stock valued at $602,000 after acquiring an additional 182,579 shares during the period. Finally, Macquarie Group Ltd. raised its holdings in STRATA Skin Sciences by 89.7% in the 2nd quarter. Macquarie Group Ltd. now owns 134,033 shares of the medical device company’s stock valued at $275,000 after acquiring an additional 63,393 shares during the period. 27.47% of the stock is currently owned by hedge funds and other institutional investors.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.
Recommended Story: Diversification in Your Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.